- Home
- PODC vs IMMX Comparison
PODC vs IMMX Comparison
Compare PODC & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- IMMX
- Stock Information
- Founded
- PODC 2013
- IMMX 2014
- Country
- PODC United States
- IMMX United States
- Employees
- PODC N/A
- IMMX N/A
- Industry
- PODC
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- PODC
- IMMX Health Care
- Exchange
- PODC Nasdaq
- IMMX Nasdaq
- Market Cap
- PODC 44.1M
- IMMX 50.1M
- IPO Year
- PODC N/A
- IMMX 2021
- Fundamental
- Price
- PODC $1.58
- IMMX $1.75
- Analyst Decision
- PODC Strong Buy
- IMMX Strong Buy
- Analyst Count
- PODC 1
- IMMX 1
- Target Price
- PODC $5.00
- IMMX $7.00
- AVG Volume (30 Days)
- PODC 24.4K
- IMMX 47.5K
- Earning Date
- PODC 02-12-2025
- IMMX 05-08-2025
- Dividend Yield
- PODC N/A
- IMMX N/A
- EPS Growth
- PODC N/A
- IMMX N/A
- EPS
- PODC N/A
- IMMX N/A
- Revenue
- PODC $49,729,000.00
- IMMX N/A
- Revenue This Year
- PODC $20.42
- IMMX N/A
- Revenue Next Year
- PODC $18.84
- IMMX N/A
- P/E Ratio
- PODC N/A
- IMMX N/A
- Revenue Growth
- PODC 22.98
- IMMX N/A
- 52 Week Low
- PODC $1.10
- IMMX $1.26
- 52 Week High
- PODC $2.85
- IMMX $3.13
- Technical
- Relative Strength Index (RSI)
- PODC 38.97
- IMMX 41.38
- Support Level
- PODC $1.31
- IMMX $1.64
- Resistance Level
- PODC $1.60
- IMMX $1.90
- Average True Range (ATR)
- PODC 0.18
- IMMX 0.14
- MACD
- PODC -0.01
- IMMX 0.00
- Stochastic Oscillator
- PODC 25.93
- IMMX 10.44
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.